4.5 Article

Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

期刊

CLINICAL EPIDEMIOLOGY
卷 14, 期 -, 页码 369-384

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/CLEP.S323292

关键词

OHDSI; OMOP CDM; descriptive epidemiology; real world data; real world evidence; open science

资金

  1. Innovative Medicines Initiative 2 Joint Undertaking (JU) [806968]
  2. European Union
  3. EFPIA
  4. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
  5. Health Department from the Generalitat de Catalunya
  6. Bill & Melinda Gates Foundation [INV-016284, INV-016201, INV-019257, INV-016910]
  7. National Key Research & Development Program of China [2018YFC0116901]
  8. University of Oxford
  9. Gates Foundation [INV-016910]
  10. National Center for Advancing Translational Sciences (NCATS), National Institutes of Health [UL1TR002369]
  11. Bio Industrial Strategic Technology Development Program by the Ministry of Trade, Industry Energy [20003883]
  12. Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea [HR16C0001]
  13. US National Institutes of Health
  14. US Department of Veterans Affairs
  15. Bill and Melinda Gates Foundation [INV-016201, INV-016284, INV-019257, INV-016910] Funding Source: Bill and Melinda Gates Foundation

向作者/读者索取更多资源

This study utilizes the Observational Health Data Sciences and Informatics (OHDSI) framework to standardize and analyze real-world data on COVID-19. The findings reveal global variations in comorbidities, symptoms, and clinical presentations among patients. The study provides a global, multi-center perspective on the progression, management, and evolution of COVID-19.
Purpose: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) Characterizing Health Associated Risks and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID19 RWD. Patients and Methods: We conducted a descriptive retrospective database study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub. We identified three non mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19, and 113,627 hospitalized with COVID-19 requiring intensive services. Results: We aggregated over 22,000 unique characteristics describing patients with COVID-19. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts and are readily available online. Globally, we observed similarities in the USA and Europe: more women diagnosed than men but more men hospitalized than women, most diagnosed cases between 25 and 60 years of age versus most hospitalized cases between 60 and 80 years of age. South Korea differed with more women than men hospitalized. Common comorbidities included type 2 diabetes, hypertension, chronic kidney disease and heart disease. Common presenting symptoms were dyspnea, cough and fever. Symptom data availability was more common in hospitalized cohorts than diagnosed. Conclusion: We constructed a global, multi-centre view to describe trends in COVID-19 progression, management and evolution over time. By characterising baseline variability in patients and geography, our work provides critical context that may otherwise be misconstrued as data quality issues. This is important as we perform studies on adverse events of special interest in COVID-19 vaccine surveillance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据